DB-1310 by Duality Biologics (Shanghai) for Non-Small Cell Lung Cancer: Likelihood of Approval

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Non-Small Cell Lung Cancer.

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer | Psychedelic Invest

NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company’s interim Chief Financial

February 7, 2024

High dietary intake of fish and vegetables in infancy may protect against IBD

Having a high dietary intake of fish and vegetables at 1 year of age, and a low intake of sugar beverages, seems to protect against

January 31, 2024

Toripalimab by Shanghai Junshi Biosciences for Ureter Cancer: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

November 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.